Sanofi : Dupixent Shows Superior Results To Xolair In Phase 4 Study For Sinus And Asthma Treatment
15/6 18:25
(RTTNews) - Sanofi (SNYNF, SNY) and Regeneron Pharmaceuticals Inc. (REGN) presented positive results from the EVEREST Phase 4 study involving adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the study, Dupixent (dupilumab) outperforme...